Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) – HC Wainwright raised their Q2 2023 earnings per share estimates for Paratek Pharmaceuticals in a report issued on Wednesday, May 10th. HC Wainwright analyst E. Arce now anticipates that the specialty pharmaceutical company will earn ($0.30) per share for the quarter, up from their previous forecast of […]